InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,576.98
(
0.07%
)
US TECH 100
19,907.60
(
0.07%
)
Dow Jones
39,291.97
(
-0.13%
)
Brent Oil
84.49
(
-1.09%
)
Bitcoin
57,825.98
(
1.98%
)
Post# of 252532
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 119999
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: NP1986 post# 145967

Tuesday, 07/24/2012 5:37:58 PM

Tuesday, July 24, 2012 5:37:58 PM

Post# of 252532

GILD may also have new single-tablet regimens containing GS-7340 by the time Merck's putative combo is ready to hit the market.

Absolutely! GS-7340 is quite important to GILD’s HIV future insofar as the US CoM patents on Viread expire in 2017 and the other Orange Book patents on Viread and Emtriva strike me as weak.

For want of a better name, I refer to the potential 4-in-1 combination of Elvitegravir, GS-7340, Emtriva, and Cobicstat as Quad Prime (#msg-71273907).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up